Sanofi Stock News

Sanofi recognized by S&P as one of the most sustainability-committed companies

These 2 Fast-Growing REITs Win Despite Inflation

Sanofi (SNY) has filed a Citizen Petition with the FDA asking the agency to change the labeling of Seqirus Fluad flu vaccines as a confirmatory post-market study failed to confirm benefit.

Can these health care stocks climb this month?

Check out the story - Adagene, Sanofi signs collaboration and license deal worth up to $2.5bn on Business-News-Today.com posted under Pharma Industry News.

These three stocks are solid value picks in different areas of healthcare.

Sanofi with ticker code (SNY) have now 4 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. Given that the stocks previous close was at 50.18 this indicates there is a potential upside of 26.8%. The 50 day MA is 51.58 while the 200 day moving average is 50.94. The market capitalisation for the company is $121,066m. You can visit the company''s website by visiting: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $153,516m based on the market concensus. Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

AstraZeneca Plc (NASDAQ: AZN ) and Sanofi SA (NASDAQ: SNY ) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory syncytial virus (RSV). The data showed that a single dose of nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% compared to placebo. The … Full story available on Benzinga.com

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.

AstraZeneca (AZN) and Sanofi''s (SNY) single dose antibody nirsevimab met the main goal of a phase 3 trial called MELODY by reducing respiratory tract infections ((LRTI)) caused by…

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

Attorneys representing individuals living with diabetes against the pharma defendants seek certification in class-action lawsuit Attorneys at Hagens Berman representing a proposed class of insulin purchasers in a lawsuit against Sanofi, Novo Nordisk and Eli Lilly for systematic overpricing of insulin have sought to certify the lawsuit''s class, just as President Joe Biden highlighted the need to "cap the cost of insulin" in his Mar. 1, 2022 State of the Union. "We filed our motion for class certification at the exact moment President Biden addressed the nation regarding the shocking price hikes of insulin," said Steve Berman , managing partner and co-founder of Hagens Berman. "In our lawsuit against the big three makers of insulin – Sanofi, Novo Nordisk and Eli Lilly – we stand with the president and his mission of stopping the rip off, once and for all." Berman serves as court-appointed co-lead counsel representing insulin purchasers in the lawsuit. "Our clients living with diabetes have been imprisoned by this racket orchestrated by insulin makers that forces them to pay hundreds of dollars a month just to stay alive, when a vial of insulin is in fact incredibly cheap to make," Berman added. "We ask the court to approve this class of folks trapped paying the phony list price for insulin and return to them what they''ve lost over years of overpricing." The law firm filed the first-of-its-kind lawsuit in 2017 in the U.S.

Sanofi SA (NASDAQ: SNY ) has signed a collaboration with Adagene Inc (NASDAQ: ADAG ) to advance two preclinical immuno-oncology candidates and an option to develop two more. Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones. Under the terms of the agreement, … Full story available on Benzinga.com